Form 4: Kymera Therapeutics Director Booth Bruce Sells Shares Under 10b5-1 Trading Plans

Director Booth Bruce of Kymera Therapeutics sold shares of common stock on July 9, 2024, through pre-arranged Rule 10b5-1 trading plans.

Summary

• On July 9, 2024, Booth Bruce, a director of Kymera Therapeutics, executed multiple sales of common stock.
• These transactions were conducted under pre-existing Rule 10b5-1 trading plans adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
• The sales were executed at varying weighted average prices, ranging from $34.96 to $39.85 per share.
• The total number of shares sold from Atlas Venture Fund X, L.P. was 375,184.
• The total number of shares sold from Atlas Venture Opportunity Fund I, L.P. was 79,015.
• Following these transactions, Booth Bruce indirectly holds 4,269,602 shares through Atlas Venture Fund X, L.P. and 723,246 shares through Atlas Venture Opportunity Fund I, L.P.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company directors are a normal part of business. The fact that these sales were executed under a 10b5-1 trading plan suggests that the director did not have any inside information at the time of the sales.

Stakeholder Impact

• The stock sales by a director could potentially create short-term selling pressure on the stock.

Key Dates